Publications by authors named "Kisho Miyasako"
Preemptive regenerative medicine using mesenchymal stem cells (MSCs) may provide a novel therapeutic approach to prevent the progression from organ damage to organ failure. Although immunosuppressive drugs are often used in patients with organ disorder, their impact on MSC therapy remains unclear. We investigated the effects of immunosuppressive drugs on the therapeutic efficacy of MSCs.
View Article and Find Full Text PDFArticle Synopsis
- Mesenchymal stem cells (MSCs), specifically adipose-derived (ADSCs) and bone marrow-derived (BMSCs), both have potential in treating renal fibrosis, but the relative effectiveness is uncertain.
- In experiments, ADSCs demonstrated a stronger ability to inhibit renal fibrosis compared to BMSCs when cultured in serum-containing medium, but both types were equally effective in serum-free conditions.
- The study also highlighted a greater risk of pulmonary embolism in mice treated with ADSCs, indicating that while they may be more effective antifibrotically, the risk factors need to be carefully considered in clinical settings.
Article Synopsis
- Fibrosis is a key factor in the transition from chronic organ injury to organ failure, often due to ongoing inflammation, and adipose-derived mesenchymal stem cells (ASCs) show potential as a treatment to mitigate this progression.
- This study explores the differences between ASCs obtained from the superficial and deep layers of abdominal fat, comparing their characteristics and therapeutic capabilities.
- Methods included analyzing cell properties, their effects on immune response, and conducting in vivo tests in a rat model with kidney injury to assess the impact of Sup-ASCs versus Deep-ASCs on fibrosis.
Article Synopsis
- Mesenchymal stem cells (MSCs) show promise for treating acute kidney injury (AKI) and preventing it from progressing to chronic kidney disease (CKD).
- In a study with rats, MSCs injected into the renal artery were more effective at reducing kidney damage compared to those injected via the inferior vena cava.
- The renal artery injections allowed MSCs to persist longer in the injured kidneys, revealing changes in their localization and suggesting their antifibrotic benefits could be key in addressing kidney injury.
Background: Primary coenzyme Q10 (CoQ10) deficiency of genetic origin is one of a few treatable focal segmental glomerulosclerosis (FSGS). Renal morphologic evidence for COQ8B mutation and CoQ10 deficiencies of other gene mutations is assessed using electron microscopy with marked increase of abnormal-shaped mitochondria in podocytes. However, light microscopic morphologic features of deficiencies other than FSGS have not been reported.
View Article and Find Full Text PDF